Moreover, in a meta-analysis of 69 studies with a total of 5736 patients, Lee et al. reported that the ctDNA mutation rates of TP53, PIK3CA and ESR1 were roughly 38%, 27% and 32%, respectively, concluding that these rates were too low for application in BC screening [41]. This evidence concerns the gene ESR1 and breast cancer.